Endoscopy 2008; 40(12): 1008-1015
DOI: 10.1055/s-0028-1103416
Total Barrett Eradication review section

© Georg Thieme Verlag KG Stuttgart · New York

Histopathology of Barrett’s esophagus after ablation and endoscopic mucosal resection therapy

R.  D.  Odze1 , G.  Y.  Lauwers2
  • 1Brigham and Women's Hospital, Boston, Massachusetts, USA
  • 2Massachusetts General Hospital, Boston, Massachusetts, USA
Further Information

Publication History

Publication Date:
08 December 2008 (online)

This review focuses on the histopathological evaluation of endoscopic mucosal resection (EMR) specimens in Barrett’s esophagus, and on the histopathological, biological, and molecular properties of postablation Barrett’s esophagus. EMR may be used for both diagnostic and therapeutic purposes. Diagnostic accuracy regarding the grade and stage of neoplasms is improved with the use of EMR, but the value of this technique for treatment is more controversial because of the high prevalence rate of positive margins and the rate of metachronous lesions found elsewhere in the esophagus during follow-up. Ablation techniques, such as argon plasma coagulation, photodynamic therapy, and radiofrequency ablation, are used increasingly for the treatment of Barrett’s esophagus and related neoplasms, often in combination with EMR. A common problem after use of these techniques is the development of islands of neosquamous epithelium (NSE) which can overlie buried Barrett’s (and/or dysplasia) epithelium. This is, therefore, concealed to the endoscopist’s view and may be allowed to progress to cancer without detection. NSE is histologically similar to normal esophageal squamous epithelium and does not possess the molecular aberrations characteristic of Barrett’s esophagus. In contrast, residual nonburied Barrett’s esophagus shows persistent pathologic and molecular abnormalities and may progress to cancer upon long term follow-up. The biological potential and rate of progression of nonburied residual Barrett’s esophagus following ablation is unclear, but some preliminary studies suggest that the risk may decrease. Buried nondysplastic Barrett’s esophagus appears to show decreased biological potential and this may be related to protection from the contents of the lumen by the barrier function of the overlying NSE. On the other hand, anecdotal reports have suggested that buried dysplasia may progress to cancer in some instances.

References

  • 1 Wang K, Sampliner R. Updated guidelines 2008 for the diagnosis, surveillance, and therapy of Barrett’s esophagus.  Am J Gastroenterol. 2008;  103 788-797
  • 2 British Society of Gastroenterology Guidelines for the diagnosis and management of Barrett’s columnar-lined oesophagus. http://www.bsg.org.uk/pdf_word_docs/Barretts_Oes.pdf; Stand: 2005
  • 3 Kelty C, Gough M, Van Wyk Q. Barrett’s oesophagus: Intestinal metaplasia is not essential for cancer risk.  Scan J Gastroenterol. 2007;  42 1271-1274
  • 4 Takubo K, Aida J, Naomoto Y. et al . Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma.  Hum Pathol. 2008; 
  • 5 Jones T F, Sharma P, Daaboul B. et al . Yield of intestinal metaplasia in patients with suspected short-segment Barrett’s esophagus (SSBE) on repeat endoscopy.  Dig Dis Sci. 2002;  47 2108-2111
  • 6 Harrison R, Perry I, Haddadin W. et al . Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies.  Am J Gastroenterol. 2007;  102 1154-1161
  • 7 Oberg S, Johansson J, Wenner J. et al . Endoscopic surveillance of columnar-line esophagus: frequency of intestinal metaplasia detection and impact of antireflux surgery.  Ann Surg. 2001;  234 619-626
  • 8 Chandrasoma P, Der R, Dalton P. Distribution and significance of epithelial types in columnar-lined esophagus.  Am J Surg Pathol. 2001;  25 1188-1193
  • 9 Odze R D. Update on the diagnosis and treatment of Barrett’s esophagus and related neoplastic precursor lesions.  Arch Pathol Lab Med. 2008;  132 (10) 1577-1585
  • 10 Hahn H, Shahsafaei A, Odze R D. Vascular and lymphatic properties of the superficial and deep lamina propria in Barrett’s esophagus.  Am J Surg Pathol. 2008;  32 1454-1461
  • 11 Glickman J N, Chen Y Y, Wang H H. et al . Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett’s esophagus.  Am J Surg Pathol. 2001;  25 569-578
  • 12 Westerterp M, Koppert L B, Buskens C J. et al . Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction.  Virchows Arch. 2005;  446 497-504
  • 13 Reid B J, Haggitt R C, Rubin E C. et al . Observer variation in the diagnosis of dysplasia in Barrett’s esophagus.  Hum Pathol. 1988;  19 166-178
  • 14 Schlemper R J, Riddell R H, Kato Y. et al . The Vienna classification of gastrointestinal epithelial neoplasia.  Gut. 2000;  47 251-255
  • 15 Odze R D. Diagnosis and grading of dysplasia in Barrett’s oesophagus.  J Clin Pathol. 2006;  59 1029-1038
  • 16 Montgomery E, Bronner M P, Goldblum J R. et al . Reproducibility of the diagnosis of dysplasia in Barrett’s esophagus: a reaffirmation.  Hum Pathol. 2001;  32 368-378
  • 17 Lomo L, Blount P L, Sanchez C A. et al . Crypt dysplasia with surface maturation: a clinical, pathologic and molecular study of a Barrett’s esophagus cohort.  Am J Surg Pathol. 2006;  30 423-435
  • 18 Srivastava A, Hornick J L, Li X. et al . Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett’s esophagus.  Am J Gastroenterol. 2007;  102 483-493
  • 19 Skacel M, Petras R E, Gramlich T L. et al . The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression.  Am J Gastroenterol. 2000;  95 3383-3387
  • 20 Kerkhof M, Van Dekken H, Steyerberg E W. et al . Grading of dysplasia in Barrett’s oesophagus: Substantial interobserver variation between general and gastrointestinal pathologists.  Histopathology. 2007;  50 920-927
  • 21 Nijhawan P K, Wang K K. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett’s esophagus.  Gastrointest Endosc. 2000;  52 328-332
  • 22 Mino-Kenudson M, Brugge W R, Puricelli W P. et al . Management of superficial Barrett’s epithelium-related neoplasms by endoscopic mucosal resection: clinicopathologic analysis of 27 cases.  Am J Surg Pathol. 2005;  29 680-686
  • 23 Peters F P, Brakenhoff K PM, Curvers W L. et al . Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett’s esophagus.  Gastrointest Endosc. 2008;  67 604-609
  • 24 Lauwers G Y, Ban S, Mino M. et al . Endoscopic mucosal resection for gastric epithelial neoplasms: a study of 39 cases with emphasis on the evaluation of specimens and recommendations for optimal pathologic analysis.  Mod Pathol. 2004;  17 2-8
  • 25 Conio M, Repici A, Cestari R. et al . Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma occurring in Barrett’s esophagus.  Gastrointest Endosc. 2004;  59 AB253 [W1549]
  • 26 Larghi A, Lightdale C J, Memeo L. et al . EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett’s esophagus.  Gastrointest Endosc. 2005;  62 16-23
  • 27 Hull M J, Mino-Kenudson M, Nishioka N S. et al . Endoscopic mucosal resection: an improved diagnostic procedure for early gastroesophageal epithelial neoplasms.  Am J Surg Pathol. 2006;  30 114-118
  • 28 Mino-Kenudson M, Ohana M, Ban S. et al . Barrett esophagus associated neoplasms treated by photodynamic therapy: determination of limiting factors [abstract].  Lab Invest. 2006;  86 114A (Abstract 517)
  • 29 Mandal R V, Forcione D G, Brugge W R. et al . Effect of tumor characteristics and duplication of the muscularis mucosae on the endoscopic staging of superficial Barrett esophagus-related neoplasia.  Am J Surg Pathol. 2008;  In press
  • 30 Ell C, May A, Pech O. et al . Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer).  Gastrointest Endosc. 2007;  65 3-10
  • 31 Vieth M, Ell C, Gossner L. et al . Histological analysis of endoscopic resection specimens from 326 patients with Barrett’s esophagus and early neoplasia.  Endoscopy. 2004;  36 776-781
  • 32 Pacifico R J, Wang K K, Wongkeesong L M. et al . Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett’s esophagus.  Clin Gastroenterol Hepatol. 2003;  1 252-257
  • 33 Prasad G A, Buttar N S, Wongkeesong L M. et al . Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett’s esophagus.  Am J Gastroenterol. 2007;  102 2380-2386
  • 34 May A, Gossner L, Behrens A. et al . A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus.  Gastrointest Endosc. 2003;  58 167-175
  • 35 Berenson M M, Johnson T D, Markowitz N R. et al . Restoration of squamous mucosa after ablation of Barrett’s esophageal epithelium.  Gastroenterology. 1993;  104 1686-1691
  • 36 Hornick J L, Blount P L, Sanchez C A. et al . Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett’s esophagus.  Am J Surg Pathol. 2005;  29 372-380
  • 37 Ban S, Mino M, Nishioka N. et al . Histopathologic aspects of photodynamic therapy for dysplasia and early adenocarcinoma arising in Barrett’s esophagus.  Am J Surg Pathol. 2004;  28 1466-1473
  • 38 Sampliner R, Fass R. Partial regression of Barrett’s esophagus – an inadequate endpoint.  Am J Gastroenterol. 1993;  88 2092-2094
  • 39 Biddlestone L, Barham C, Wilkinson S. et al . The histopathology of treated Barrett’s esophagus: squamous reepithelialization after acid suppression and laser and photodynamic therapy.  Am J Surg Pathol. 1998;  22 239-245
  • 40 Sharma V K, Wang K K, Overhold B F. et al . Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients.  Gastrointest Endosc. 2007;  65 185-195
  • 41 Sharma V K, Kim H J, Das A. et al . A prospective pilot trial of ablation of Barrett’s esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system).  Endoscopy. 2008;  40 380-387
  • 42 Gondrie J J, Pouw R E, Sondermeijer C M. et al . Stepwise circumferential and focal ablation of Barrett’s esophagus with high-grade dysplasia: results of the first prospective series of 11 patients.  Endoscopy. 2008;  40 359-369
  • 43 Gondrie J J, Pouw R E, Sondermeijer C M. et al . Effective treatment of early Barrett neoplasia with stepwise circumferential and focal ablation using the HALO system.  Endoscopy. 2008;  40 370-379
  • 44 Gossner L, Stolte M, Sroka R. et al . Photodynamic ablation of high-grade dysplasia and early cancer in Barrett’s esophagus by means of 5-amino-levulinic acid.  Gastroenterology. 1998;  114 448-455
  • 45 Barham C P, Jones R L, Biddlestone L R. et al . Photothermal laser ablation of Barrett’s oesophagus: endoscopic and histological evidence of squamous re-epithelialisation.  Gut. 1997;  41 281-284
  • 46 Van Laethem J L, Peny M O, Salmon I. et al . Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett’s oesophagus.  Gut. 2000;  46 574-577
  • 47 Ackroyd R, Brown N J, Davis M F. et al . Photodynamic therapy for dysplastic Barrett’s oesophagus: a prospective, double blind, randomised, placebo controlled trial.  Gut. 2000;  47 612-617
  • 48 Sampliner R E, Faigel D, Fennerty M B. et al . Effective and safe endoscopic reversal of nondysplastic Barrett’s esophagus with thermal electrocoagulation combined with high-dose acid inhibition: A multicenter study.  Gastrointest Endosc. 2001;  53 554-558
  • 49 Peters F TM, Ganesh S, Kuipers E J. et al . Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study.  Gut. 1999;  45 489-494
  • 50 Paulson T, Xu L J, Sanchez C. et al . Neosquamous epithelium does not typically arise from Barrett’s epithelium.  Clin Cancer Res. 2006;  12 1701-1706
  • 51 Leedham S J, Preston S L, McDonald S AC. et al . Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett’s oesophagus.  Gut. 2008;  57 1041-1048
  • 52 Finkelstein S D, Lyday W D. The molecular pathology of radiofrequency mucosal ablation of Barrett’s esophagus.  Gastroenterology. 2008;  134 A437
  • 53 Sarosi G, Brown G, Jaiswal K. et al . Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett’s esophagus.  Dis Esoph. 2008;  21 43-50
  • 54 Houghton J M, Stoicov C, Nomura S. et al . Gastric cancer originating from bone marrow-derived cells.  Science. 2004;  306 1568-1571
  • 55 Thiery J P. Epithelial-mesenchymal transitions in development and pathologies.  Curr Opin Cell Biol. 2003;  15 740-746
  • 56 Gillen P, Kneeling P, Byrne P J. et al . Experimental columnar metaplasia in the canine oesophagus.  Br J Surg. 1988;  75 113-115
  • 57 Sharma P, Morales T G, Bhattacharyya A. et al . Squamous islands in Barrett’s esophagus: what lies underneath?.  Am J Gastroenterol. 1998;  93 332-335
  • 58 Krishnadath K K, Wang K K, Taniguchi K. et al . Persistent genetic abnormalities in Barrett’s esophagus after photodynamic therapy.  Gastroenterology. 2000;  119 624-630
  • 59 Reid B J, Blount P L, Feng Z. et al . Optimizing endoscopic biopsy detection of early cancers in Barrett’s high-grade dysplasia.  Am J Gastroenterol. 2000;  95 3089-3096
  • 60 Hornick J L, Mino-Kenudson M, Lauwers G. et al . Buried Barrett’s epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities.  Am J Gastroenterol. 2008;  103 38-47
  • 61 Panjehpour M, Coppola D, Overholt B. et al . Photodynamic therapy of Barrett’s esophagus: ablation of Barrett’s mucosa and reduction in p53 protein expression after treatment.  AntiCancer Res. 2008;  28 485-490
  • 62 Hage M, Siersema P, Vissers K. et al . Genomic analysis of Barrett’s esophagus after ablative therapy: Persistence of genetic alterations at tumor suppressor loci.  Int J Cancer. 2006;  118 155-160
  • 63 Hage M, Siersema P, Vissers K. et al . Molecular evaluation of ablative therapy of Barrett’s oesophagus.  J Pathol. 2005;  205 57-64

R. D. OdzeMD 

Brigham and Women’s Hospital
Gastrointestinal Pathology

75 Francis St.
Boston, MA 02115
USA

Fax: 01-617-278-6950

Email: rodze@partners.org

    >